+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist

Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist

Journal of Pharmacology and Experimental Therapeutics 259(1): 44-51

SR 27417 [N-(2-dimethylamino ethyl)-N-(3-pyridinyl methyl)[4- (2,4,6-triisopropylphenyl) thiazol-2-yl]amine] is the first member of a newly developed platelet-activating factor (PAF) antagonist series. It is a highly potent, competitive and selective antagonist of the binding of [3H]PAF to its receptor in rabbit platelets. It exhibits an equilibrium inhibition constant for PAF binding of 57 pM, a value that is at least 5-fold lower than that of unlabeled PAF itself. SR 27417 potently inhibited PAF-induced aggregation of rabbit and human platelets in vitro (IC50 = 0.10 and 0.50 nM, respectively) but had no effect on the action of other platelet-aggregating agents. In comparison with the triazolothienodiazepine WEB-2086, SR 27417 was 470 and 70 times more potent against PAF-induced aggregation of rabbit and human platelets, respectively. SR 27417 displayed marked in vitro inhibition of PAF-induced oxidative burst in guinea pig macrophages (IC50 = 32 nM). In an in vivo model, it protected mice from 100 micrograms/kg PAF-induced death when given i.v. (ED50 = 7.5 micrograms/kg) 5 min before PAF challenge or p.o. (ED50 = 45 micrograms/kg) 3 hr before PAF administration. SR 27417 inhibited PAF-induced death in mice with an impressive p.o. or i.v. duration of action of 30 to 48 hr. In anesthetized guinea pigs, SR 27417 inhibited i.v. and p.o. 100 ng/kg PAF-induced bronchoconstriction (ED50 = 14 and 140 micrograms/kg, respectively), hemoconcentration (ED50 = 20 and 270 micrograms/kg, respectively), thrombocytopenia (ED50 = 30 and 240 micrograms/kg, respectively) and leukopenia (ED50 = 0.1 and 1.5 mg/kg, respectively).

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 039392018

Download citation: RISBibTeXText

PMID: 1656029

Related references

SR 27417, a novel, highly potent and long-acting PAF receptor antagonist. Journal of Lipid Mediators & Cell Signalling 10(1-2): 149-150, 1994

SR 27417, a highly potent, selective and long-acting antagonist of the PAF receptor. Drugs of the Future 17(11): 1011-1018, 1992

In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation. Veterinary Research 31(2): 267-272, 2000

Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor. Journal of Pharmacology and Experimental Therapeutics 246(2): 534-541, 1988

Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist. European Journal Of Pharmacology. 325(1): 69-80, 1997

Binding of [3H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes. Biochemical Pharmacology 45(1): 51-58, 1993

Effects of Y-24180, a long-acting and potent antagonist to platelet-activating factor, on immediate asthmatic response in guinea pigs. Pharmacology 54(1): 1-7, 1997

Effects of Y-24180, a Long-Acting and Potent Antagonist to Platelet-Activating Factor, on Immediate Asthmatic Response in Guinea Pigs. Pharmacology 54(1): 1-7, 1997

Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 277(3): 1595-1606, 1996

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1 biphenyl-4-yl-1H-benzimidazole-7-carboyxlic acid. Journal of Pharmacology & Experimental Therapeutics 266(1): 114-120, 1993

Pharmacological Profiles of a Highly Potent and Long-Acting Angiotensin II Receptor Antagonist, Fimasartan, in Rats and Dogs after Oral Administration. Biological and Pharmaceutical Bulletin 40(7): 992, 2017

Pharmacological actions of Y-24180: I. A potent and specific antagonist of platelet-activating factor. Prostaglandins 40(6): 553-569, 1990

Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309. Advances in Prostaglandin Thromboxane and Leukotriene Research 21b: 943-946, 1991

Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor. Archives Internationales de Pharmacodynamie et de Therapie 308: 123-136, 1990

The effects of platelet activating factor acether on the cardiovascular system and their inhibition by a new highly specific platelet activating factor acether receptor antagonist bn 52021. Pharmacological Research Communications 18(8): 717-738, 1986